Search - tctmd.com

Displaying 501 - 520 of 1188

Sort: Relevancy | Date

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

November 15, 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

News Conference News AHA 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

Michael O'Riordan

November 13, 2021

Village-Level Intervention Nets Big BP Control Gains in Rural China

News Conference News AHA 2021

Village-Level Intervention Nets Big BP Control Gains in Rural China

November 13, 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

November 04, 2021

Zero CAC Questionable for Ruling Out Obstructive CAD in Young Adults

News Daily News

Zero CAC Questionable for Ruling Out Obstructive CAD in Young Adults

Michael O'Riordan

November 02, 2021

CVD Risk ‘Underappreciated’ After Adverse Pregnancy Outcomes

News Daily News

CVD Risk ‘Underappreciated’ After Adverse Pregnancy Outcomes

November 01, 2021

Only a Minority of Stable PCI Patients Meet ISCHEMIA Criteria, Study Contends

News Daily News

Only a Minority of Stable PCI Patients Meet ISCHEMIA Criteria, Study Contends

November 01, 2021

November 2021 News Roundup

News Opinion CV Team Dispatch

November 2021 News Roundup

November 01, 2021

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

News Daily News

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

Michael O'Riordan

October 28, 2021

Starting DOACs Early After Ischemic Stroke Appears Safe

News Daily News

Starting DOACs Early After Ischemic Stroke Appears Safe

October 21, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

News Conference News TCT 2021

EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

Michael O'Riordan

October 15, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

Failed MitraClip Is Uncommon, but Bleak When It Happens

News Conference News TCT 2021

Failed MitraClip Is Uncommon, but Bleak When It Happens

Michael O'Riordan

October 08, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.